🕒 Last update: loading…16/11/2026

Stock Carl Zeiss Meditec AG AFX.DE

Carl Zeiss Meditec AG — Investlytic score 3/5 on the five criteria.

-
-
60/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 3/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ✅ Growth passed
  • ✅ Debt passed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 66.47%

Price change 2019 → 2020: -4.22%

Price change 2020 → 2021: 69.74%

Price change 2021 → 2022: -36.22%

Price change 2022 → 2023: -16.17%

Price change 2023 → 2024: -53.95%

Price change 2024 → 2025: -12.13%

Price change 2025 → 2026: -12.20%

Price change 2026 (year to date): -11.27%

Financial growth

Revenue CAGR (8 years): 8.23%

Earnings CAGR (8 years): 1.59%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.29

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 23.18

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 1.18% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Carl Zeiss Meditec AG23.10.29+8.3 %🔒
Virbac S.A.20.00.26+6.5 %★ 4/5
Legend Biotech Corporation–0.41+60.3 %–
Option Care Health, Inc.18.40.96+18.7 %–
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Carl Zeiss Meditec AG over the latest fiscal years.

Revenue
2.5 bn USD
fiscal year 2025
Net income
156 m USD
fiscal year 2025
Net margin
6.3 %
fiscal year 2025
Average annual growth
+10.8 %
Revenue growth over 5 years
Average annual growth
+7.9 %
Revenue growth over 10 years
Market cap
3.4 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20201.5 bn135 m9.2 %n/a
20211.8 bn260 m14.3 %+23.3 %
20222.1 bn324 m15.4 %+15.5 %
20232.3 bn320 m13.9 %+9.8 %
20242.3 bn197 m8.7 %-1.1 %
20252.5 bn156 m6.3 %+7.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Carl Zeiss Meditec AG over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
41.23 EUR
DCF close to share price · share price 34.44 EUR, gap +19.7 %
Net Debt / EBITDA
0.00 x
low debt
Fiscal year20212022202320242025
Cash and investments7.4 m7.7 m10.6 m20.3 m27.3 m
Total Debt197 m219 m298 m613 m607 m
Net Debt190 m211 m287 m592 m580 m
Equity1.7 bn2.0 bn2.2 bn2.0 bn2.1 bn
Total assets2.4 bn2.8 bn3.0 bn3.4 bn3.5 bn
Operating cash flow363 m188 m251 m247 m210 m
Investments (capex)66.1 m82.0 m65.7 m86.8 m39.4 m
Free cash-flow297 m106 m137 m95.1 m170 m
Share buybacks000150 m0
Dividends paid44.7 m80.5 m98.4 m98.2 m52.5 m

Amounts in EUR, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)20.62 x
Price / book value1.41 x
Return on Equity (ROE)5.5 %
Return on Invested Capital (ROIC)0.0 %
Net margin4.4 %
Debt / equity0.00 x
Current ratio0.00 x
Interest coverage5.27 x
Free cash-flow yield9.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Carl Zeiss Meditec AG compared with its sector on the same exchange and with its main competitors.

Company P/E
23.1
28.9 % below the sector
Sector median P/E
32.5
healthcare, Xetra
Sector over 10 years
26.9
10-year median, range 20.7 to 68.4

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 16/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Carl Zeiss Meditec AG: dividend history, last distributions, stock splits and earnings releases.

Frequency
annual
Last dividend
0.550 EUR
ex-dividend on 27/03/2026
Last 12 months
0.550 EUR
number of payments: 1
Yield
1.4 %
on the last known price
Years of increases
0
consecutive
Years of payments
20
uninterrupted
00.280.550.831.102007 : 0.140 EUR2008 : 0.160 EUR20082009 : 0.180 EUR2010 : 0.180 EUR20102011 : 0.330 EUR2012 : 0.300 EUR20122013 : 0.400 EUR2014 : 0.450 EUR20142015 : 0.400 EUR2016 : 0.380 EUR20162017 : 0.420 EUR2018 : 0.550 EUR20182019 : 0.550 EUR2020 : 0.650 EUR20202021 : 0.500 EUR2022 : 0.900 EUR20222023 : 1.10 EUR2024 : 1.10 EUR20242025 : 0.600 EUR2026 : 0.550 EUR2026

Annual dividend per share (EUR), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
27/03/20260.550 EUR31/03/2026
27/03/20250.600 EUR31/03/2025
22/03/20241.10 EUR26/03/2024
23/03/20231.10 EUR27/03/2023
31/03/20220.900 EUR04/04/2022
28/05/20210.500 EUR01/06/2021
07/08/20200.650 EUR11/08/2020
20/03/20190.550 EUR22/03/2019

Earnings releases

Next release: 10/12/2026. Expected EPS: 0.48.

DatePublished EPSExpected EPSSurprise
06/08/20260.640.48+34.3 %
12/05/20260.330.27+20.4 %
12/02/2026-0.061.13-105.3 %
11/12/20250.920.68+34.9 %
07/08/20250.330.68-51.6 %
13/05/20250.520.47+11.2 %

Stock splits

DateOperation
24/10/2006split: 1,369 shares for 1,000

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Xetra
IPO: 22/03/2000
ISIN code
DE0005313704
Workforce
2,066
full-time employees
Chief executive
Markus Weber
Next earnings
10/12/2026

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Carl Zeiss Meditec AG

What is the Carl Zeiss Meditec AG share price?

Latest recorded price: 35.00 EUR on 13/11/2026, for a market cap of 3.4 bn USD.

What is the revenue of Carl Zeiss Meditec AG?

2.5 bn USD for fiscal year 2025, with net income of 156 m USD (net margin 6.3 %).

Does Carl Zeiss Meditec AG pay a dividend?

Yes. Latest dividend: 0.550 EUR per share, ex-dividend on 27/03/2026. Over 12 months: 0.550 EUR. Yield on the latest known price: 1.4 %.

When does Carl Zeiss Meditec AG report its next earnings?

The next release is expected on 10/12/2026. EPS expected by analysts: 0.48.

What is the P/E ratio of Carl Zeiss Meditec AG?

Trailing 12-month P/E of 23.1, against 32.5 for the sector median on the same exchange (10-year median: 26.9).

Is Carl Zeiss Meditec AG stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN DE0005313704) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does Carl Zeiss Meditec AG have?

2,066 full-time employees according to the latest published profile.

Who runs Carl Zeiss Meditec AG?

Markus Weber is the company's chief executive.

07

Similar stocks